天眼查商业履历信息显示，山东金城医药集团股份有限公司，成立于2004年，位于淄博市，是一家以从 事医药制造业为主的企业。企业注册资本38387.4587万人民币，实缴资本8280万人民币。公司法定代表 人为赵叶青。 通过天眼查大数据分析，山东金城医药集团股份有限公司共对外投资了14家企业，参与招投标项目15 次，知识产权方面有商标信息36条，专利信息68条，此外企业还拥有行政许可9个。 来源：金融界 金融界消息 截至2025年8月14日收盘，金城医药（300233）报收于18.01元，下跌3.07%，换手率 6.11%，成交量22.71万手，成交金额4.13亿元。 资金流向方面，今日主力资金净流出4455.59万元，占比成交额10.78%。其中，超大单净流出3516.34万 元、占成交额8.5%，大单净流出939.24万元、占成交额2.27%，中单净流出流入3045.68万元、占成交额 7.37%，小单净流入1409.91万元、占成交额3.41%。 金城医药最新一期业绩显示，截至2025一季报，公司营业总收入7.22亿元、同比减少22.52%，归属净利 润3505.48万元，同比减少57.75%，扣非净利润3 ...

金融界消息 截至2025年8月13日收盘，金城医药（300233）报收于18.58元，下跌1.12%，换手率 6.92%，成交量25.72万手，成交金额4.78亿元。 资金流向方面，今日主力资金净流出3670.70万元，占比成交额7.69%。其中，超大单净流出3722.96万 元、占成交额7.8%，大单净流入52.26万元、占成交额0.11%，中单净流出流入3139.12万元、占成交额 6.57%，小单净流入531.58万元、占成交额1.11%。 来源：金融界 天眼查商业履历信息显示，山东金城医药集团股份有限公司，成立于2004年，位于淄博市，是一家以从 事医药制造业为主的企业。企业注册资本38387.4587万人民币，实缴资本8280万人民币。公司法定代表 人为赵叶青。 通过天眼查大数据分析，山东金城医药集团股份有限公司共对外投资了14家企业，参与招投标项目15 次，知识产权方面有商标信息36条，专利信息68条，此外企业还拥有行政许可9个。 金城医药最新一期业绩显示，截至2025一季报，公司营业总收入7.22亿元、同比减少22.52%，归属净利 润3505.48万元，同比减少57.75%，扣非净利润3295 ...

Group 1 - The core point of the article is that Jincheng Pharmaceutical (300233) announced the approval of a chemical raw material drug listing application by the National Medical Products Administration [1] Group 2 - The approval notification was issued to Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd. [1]

Group 1 - Niuwei Co., Ltd. reported a net profit of 637 million yuan for the first half of 2025, representing a year-on-year increase of 30.47% [1] - The company achieved a total operating revenue of 3.404 billion yuan, up 19.96% year-on-year [1] - Niuwei specializes in the research, manufacturing, and sales of industrial valves [2] Group 2 - Shandong Haohua plans to acquire a 29% stake in Zhongyan Alkali Industry with a total investment of 2.32 billion yuan [2] - The company is involved in the production of soda ash and caustic soda [3] Group 3 - Dongfang Co., Ltd. announced a partnership with Dongfang Import and Export Company to develop overseas marketing business [38] - The company focuses on the research, production, and sales of light commercial vehicles and powertrains [38] Group 4 - Xinyuan Technology reported a net profit of 52.6 million yuan for the first half of 2025, a year-on-year increase of 10.70% [12] - The company achieved an operating revenue of 2.871 billion yuan, up 3.86% year-on-year [12] - Xinyuan provides one-stop custom development and production services for pharmaceutical companies and research institutions [12] Group 5 - Zhuhai Piano announced that its subsidiary won the operating rights project for the Baihuazhai scenic area, with an investment of no less than 400 million yuan over 20 years [21] - The company specializes in the research, manufacturing, and sales of pianos and digital musical instruments [21] Group 6 - Zhenghong Technology reported a sales revenue of 26.02 million yuan from pig sales in July, a year-on-year increase of 288.69% [16] - The company sold 63,000 pigs in total from January to July 2025, with a cumulative sales revenue of 109 million yuan, representing a year-on-year increase of 38.06% [16] - Zhenghong focuses on feed products and pig farming [17] Group 7 - ST Nuotai received the cGMP certification from Brazil's National Health Surveillance Agency for its production facility [15] - The company specializes in the research and development of peptide drugs and small molecule pharmaceuticals [15] Group 8 - Guizhou Moutai has repurchased a total of 3.4517 million shares, accounting for 0.2748% of its total share capital, with a total expenditure of 5.301 billion yuan [48][49] - The company is engaged in the production and sales of Moutai liquor and related products [49]

金城医药（300233）(300233.SZ)公告，公司全资子公司北京金城泰尔制药有限公司于近日收到国家药 品监督管理局下发的《化学原料药上市申请批准通知书》，该化学原料药名称为：乳糖酸红霉素。注射 用乳糖酸红霉素是一种大环内酯类抗生素，用于治疗较为严重的感染性疾病。 ...

Group 1 - The core point of the article is that Jincheng Pharmaceutical has received approval for its chemical raw material drug, Lactobionic Acid Erythromycin, from the National Medical Products Administration [1] - The drug is an antibiotic belonging to the macrolide class, used for treating severe infectious diseases [1]

证券代码：300233 证券简称：金城医药 公告编号：2025-055 本次金城实业系根据其自身资金需求做出的质押展期，不涉及新增融资。截至本公 告披露日，金城实业质押的股份不存在平仓风险，上述质押（展期）行为不会导致公司 实际控制权发生变更。公司将持续关注股票质押情况及质押风险情况，并按规定及时做 好相关信息披露工作，敬请投资者注意投资风险。 | | 是否 为控 | | | | | 是 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股股 | 本次 | 占其 | 占公 | 是 | 否 | | | | | | | | 东或 | | | | 否 | | | | | | | | 股东 | 第一 | 质押 | 所持 | 司总 | 为 | 为 | 质押起 | 质押到 | 展期后 | | 质押 | | | | 展期 | 股份 | 股本 | | 补 | | | 质押到 | 质权人 | | | 名称 | 大股 | 股数 | 比例 | 比例 | 限 | 充 | 始日 | 期日 | 期日 | | ...

人民财讯8月5日电，金城医药(300233)8月5日晚间公告，子公司收到乳糖酸红霉素化学原料药上市申请 批准通知书，注射用乳糖酸红霉素是一种大环内酯类抗生素，用于治疗较为严重的感染性疾病。 转自：证券时报 ...

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Erythromycin Lactobionate [2] Group 1 - The approved chemical raw material drug is Erythromycin Lactobionate [2]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing of Erythromycin Lactobionate in the domestic market, which will enhance the company's product line and market competitiveness in the chemical raw materials sector [1] Group 1 - The approval allows for the production and sale of Erythromycin Lactobionate in the domestic market [1] - This development is expected to enrich the company's product offerings [1] - The move is anticipated to improve the company's competitiveness in the chemical raw materials industry [1] Group 2 - The sales of the drug are subject to uncertainties due to national policies and changes in the market environment [1]